Hep3B hepatoma cell viability (Hep3B)

Hep3B hepatoma cell viability is a phenotypic measurement used to evaluate the survival and proliferation of the Hep3B human hepatocellular carcinoma cell line in response to pharmacological agents. The Hep3B cell line is a widely utilized in vitro model for liver cancer research, originally derived from an 8-year-old male and notable for containing integrated hepatitis B virus (HBV) genomes (Aden et al., 1979, Nature; ATCC HB-8064). Unlike specific molecular targets such as receptors or enzymes, this "target" represents a complex biological system where drug efficacy is measured by the overall reduction in cell population or metabolic activity (ChEMBL). Hep3B cells are characterized by their ability to secrete liver-specific proteins like alpha-fetoprotein (AFP) and albumin, making them relevant for studying both oncology and viral pathogenesis (Knowles et al., 1980, Science). In drug discovery, compounds like sorafenib are often screened against this cell line to determine their potential for treating hepatocellular carcinoma (PubChem). Because the readout is cell viability, the mechanism of action for interacting drugs can vary widely, ranging from cell cycle arrest to the induction of apoptosis. This phenotypic approach allows for the identification of compounds that may act through novel or multiple molecular pathways simultaneously.

Other names

Hep3B cell lineHepatocellular carcinoma cell line Hep3BHep3B viability assay

Reduction of cell viability through various mechanisms including kinase inhibition, induction of apoptosis, and cell cycle arrest.